TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases and cancer, today ...
Key Highlights: Top-line results from the confirmatory Phase III study with TALICIA ® for H. pylori infection are on track to be announced by year-end 2018, with potential NDA filing in early 2019 Positive top-line results from the Phase III study with RHB-104 for Crohn’s disease - the study ...
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
Top-line results from the ERADICATE Hp2 confirmatory Phase III study expected before year-end 2018 H. pylori bacterial infection affects over 50% of the adult population worldwide and 30-40% of the U.S. population TEL-AVIV, Israel and RALEIGH, N.C. , Oct. ...
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
RedHill will host an Analyst and Investor Webcast on TALICIA ® for H. pylori infection on Tuesday, October 30, 2018 , at 8:30 a.m. EDT Final patient assessed for primary endpoint, with top-line results expected before year-end 2018 If successful, RedHill plans to file a U.S. ...
The presentation highlighted enhanced p-values for previously reported outcomes, including the primary endpoint of clinical remission at week 26 (p=0.007) and key secondary and other efficacy endpoints of clinical response at week 26 (p=0.016), early clinical remission at week 16 (p=0.015), ...
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 10, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
TEL-AVIV, Israel and RALEIGH, N.C. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA ® for diarrhea-predominant irritable bowel syndrome (IBS-D), one of the most common gastrointestinal disorders In light of the clarity provided by the FDA regarding the clinical and regulatory pathway for ...
Menu